Indications
Telmisartan is indicated for use as a monotherapy or in conjunction with other antihypertensive agents to manage hypertension. It is also employed in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus. Furthermore, telmisartan can be utilized in the management of congestive heart failure, specifically for patients who are intolerant to ACE inhibitors.
Pharmacodynamics
Telmisartan functions as an orally active nonpeptide angiotensin II antagonist that primarily targets the AT1 receptor subtype. Among available angiotensin receptor blockers (ARBs), telmisartan demonstrates the highest affinity for the AT1 receptor while exhibiting negligible affinity for the AT2 receptor. Recent research suggests that telmisartan may also exert PPARγ agonistic effects, potentially offering advantageous metabolic impacts. PPARγ is a nuclear receptor that modulates gene transcription related to glucose and lipid metabolism, alongside anti-inflammatory responses. These potential effects are currently under investigation in clinical settings. The drug acts by inhibiting the vasoconstrictor and aldosterone secretory effects induced by angiotensin II, a principal agent in the renin-angiotensin system responsible for regulating blood pressure.
Absorption
Telmisartan displays nonlinear pharmacokinetics when administered orally across doses ranging from 20 mg to 160 mg, with both Cmax and AUC showing disproportionately higher increments at elevated doses. Following once-daily administration, telmisartan achieves trough plasma concentrations at approximately 10% to 25% of the peak plasma levels. Its absolute bioavailability varies with dose, measured at 42% for a 40 mg dose and 58% for a 160 mg dose. The presence of food marginally reduces bioavailability, with decreases of around 6% and 20% for the 40 mg and 160 mg doses, respectively, when taken with a meal.
Metabolism
Telmisartan undergoes minimal metabolism via conjugation, resulting in an inactive acyl-glucuronide metabolite. This glucuronide of the parent compound is the sole metabolite observed in human plasma and urine. Notably, telmisartan's metabolism does not involve the cytochrome P450 isoenzymes.
Mechanism of Action
Telmisartan functions by selectively and reversibly binding to angiotensin II AT1-receptors located in vascular smooth muscle and the adrenal gland, thereby inhibiting the effects of angiotensin II. Angiotensin II is known for its vasoconstrictive properties and its role in stimulating aldosterone synthesis and release. By blocking its activity, telmisartan effectively reduces systemic vascular resistance. Notably, telmisartan does not interfere with the angiotensin-converting enzyme or other hormone receptors and ion channels. Additionally, research indicates that telmisartan acts as a partial agonist of peroxisome proliferator-activated receptor gamma (PPARγ), a target known for its role in antidiabetic therapies. This interaction suggests that telmisartan may enhance carbohydrate and lipid metabolism and help manage insulin resistance, offering benefits without the adverse effects commonly associated with full PPARγ activators.
